Better Therapeutics, Inc. · OTC:BTTX

Better Therapeutics — Corporate Update (March 2022)

10 slides from Better Therapeutics's corporate update, Mar 15, 2022

  1. Slide 1: Primary Endpoint Day 90 Analysis

    Exhibit 99.2 MARCH 15, 2022 Primary Endpoint Day 90 Analysis

  2. Slide 2: Disclaimer

    Disclaimer This presentation (“Presentation”) is for informational purposes only. The information contained herein does not purport to be all-inclusive and neither Better Therapeutics, Inc. (“BetterTX” or the “Company“) nor any of its respective affiliates nor any of its or their control persons, of

  3. Slide 3: Better Therapeutics

    Better’ THERAPEUTICS

  4. Slide 4: Baseline Characteristics: Diverse, nationally representative patient population

    Baseline Characteristics Diverse, nationally representative patient population recruited from 6 states Standard of Care BT-001 Overall Parameter / Category Statistic (n=343) (n=326) (n=669) Age (yrs) Mean 57.5 57.6 57.5 % Female % 56.3% 56.1% 56.2% Race % White 60.1% 59.5% 59.8% Black or African Ame

  5. Slide 5: Baseline Characteristics: Long-standing T2 diabetes, high cardiovascular risk

    Baseline Characteristics Participants had long-standing T2 diabetes, high cardiovascular risk, multiple comorbidities and extensive medication use Standard of Care BT-001 Overall Parameter / Category Statistic (n=343) (n=326) (n=669) BMI (kg/m2) Mean 35.0 35.0 35.0 Baseline HbA1c (%) Mean 8.1% 8.2%

  6. Slide 6: Change in A1c (-0.4%) was Clinically Meaningful and Highly Statistically Significant

    Change in A1c (-0.4%) was Clinically Meaningful and Highly Statistically Significant Standard of Care BT-001 Statistic Difference P-value (n=307) (n= 295) Baseline Mean (SD) 8.1% (0.9) 8.2% (0.9) Day 90 Mean (SD) 8.2% (1.4) 7.9% (1.3) Day 90, Change From Baseline Intent to Treat Population Mean (SD)

  7. Slide 7: Safety Data Summary

    Safety Data Summary Study demonstrates expected profile in T2DM population. No meaningful differences between groups. No events related to BT-001 device. Standard of Care BT-001 Overall (n=343) (n=326) (n=669) Number of Subjects who Subjects Events Subjects Events Subjects Events Experienced: n (%)

  8. Slide 8: Dose Response of nCBT

    Dose Response of nCBT Higher dose associated with larger improvements, without increased adverse events Low Use of Behavior Moderate Use of High Use of Therapy Behavior Therapy Behavior Therapy < 5 lessons 5-10 lessons >10 lessons 0- 0.04% -0.1 % Mean Change in A1c in -0.2 Change -0.21% Mean -0.3 %

  9. Slide 9: Patient Engagement

    Patient Engagement Pilot 4.9 7.5 5 9 68% 64% Pivotal 5.7 7.5 45 64% 89% Minutes / Day Percent of Patients Average Lessons Percent of Patients Using Net Promoter Using BT-001 as Completed the App at Week 10 Score Intended Better 9

  10. Slide 10: = | ll B’

    = | ll B’

Better Therapeutics — Corporate Update (March 2022) on 6ix